| Literature DB >> 33816017 |
Uğur Küçük1, Ali Duygu2, Bahadır Kırılmaz1.
Abstract
Background Increased life expectancy across the world has resulted in an increase in the proportion of the elderly population who are lost to heart diseases. Advanced age and comorbidities are believed to change the response to treatments. In this study, we aimed to investigate the effects of surgical and medical treatments on the mortality of stable coronary diseases. Methods A total of 150 geriatric patients who underwent coronary angiography (CAG) were followed up in our cardiology clinic. Patients who decided to undergo coronary artery bypass graft (CABG) surgery after CAG and were willing to undergo the operation were assigned to group 1, whereas those who were unwilling to undergo the operation were not eligible for percutaneous coronary intervention and were followed up medically, and were assigned to group 2. Keeping the primary goal as mortality rates, both the groups were compared using medical records for three years after the treatment. Results After three years, the overall mortality rate included six patients (16%) in the CABG group versus 63 patients (55%) in the medical therapy group (p < 0.001). The CABG therapy was found to be significantly and independently associated with first- and third-year mortality (risk ratio: 0.064, 95% confidence interval: 0.009-0.467, p = 0.007; risk ratio: 0.305, 95% confidence interval: 0.151-0.615, p < 0.001, respectively). Kaplan-Meier analysis for first- and third-year all-cause mortality rates led to significant results and curves between the groups. Conclusion Our study revealed that compared to CABG surgery in the treatment of coronary artery disease in geriatric patients, medical treatment is associated with poor outcomes in terms of mortality in long-term follow-up.Entities:
Keywords: coronary artery bypass graft surgery; geriatric; mortality
Year: 2021 PMID: 33816017 PMCID: PMC8011467 DOI: 10.7759/cureus.13618
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Baseline clinical characteristics, laboratory values, and preadmission medications of the patients
CABG: coronary artery bypass grafting; WBC: white blood cell; DM: diabetes mellitus; HT: hypertension; LVEF: left ventricle ejection fraction; ACEI: angiotensinogen-converting enzyme inhibitor; ARB: angiotensin receptor blocker; ASA: acetylsalicylic acid; LDL-C: low-density lipoprotein cholesterol; Syntax: the synergy between percutaneous coronary intervention with taxus and cardiac surgery; LDL: low-density lipoprotein; CPB: cardiopulmonary bypass; IT: intubation time; ICU: intensive care unit
| Variables | CABG (n = 38) | Medical therapy (n = 112) | p |
| Age (years) | 78.8 ± 3.3 | 79.1 ± 3.1 | 0.623 |
| Female n (%) | 15 (10) | 44 (29.3) | 0.984 |
| HT n (%) | 24 (16) | 60 (40) | 0.304 |
| DM n (%) | 10 (6.7) | 35 (23.3) | 0.566 |
| Systolic blood pressure (mmHg) | 133.68 ± 9.13 | 133.15 ± 9.40 | 0.794 |
| Diastolic blood pressure (mmHg) | 77.32 ± 6.48 | 77.17 ± 7.58 | 0.925 |
| Current smoker n (%) | 13 (8.7) | 58 (38.7) | 0.061 |
| Serum glucose (mg/dL) | 127.42 ± 32.15 | 126.31 ± 32.40 | 0.855 |
| Creatinine (mg/dL) | 0.97 ± 0.27 | 1.11 ± 0.40 | 0.133 |
| TSH (mU/L) | 0.57 ± 0.43 | 1.76 ± 0.88 | 0.078 |
| LDL-C (mg/dL) | 120.29 ± 33.79 | 128.09 ± 39.09 | 0.148 |
| Hemoglobin (g/dL) | 12.18 ± 1.81 | 12.20 ± 1.84 | 0.795 |
| WBC count (x103/µL) | 7.76 ± 2.10 | 8.19 ± 2.37 | 0.401 |
| Neutrophil count (×103/L) | 5.14 ± 2.51 | 5.22 ± 2.31 | 0.803 |
| Lymphocyte count (×103/L) | 1.74 ± 0.53 | 1.71 ± 0.59 | 0.927 |
| Thrombocyte count (x103/µL) | 225.07 ± 68.84 | 223.99 ± 73.04 | 0.936 |
| LVEF (%) | 50.92 ± 8.5 | 48 ± 8.9 | 0.081 |
| Syntax score | 23.24 ± 6.10 | 24.48 ± 6.29 | 0.290 |
| Medication n (%) | |||
| ASA | 28 (18.7) | 85 (56.7) | 0.785 |
| ACEI/ARB | 24 (16) | 60 (40) | 0.304 |
| Beta blocker | 5 (12.5) | 14 (35) | 0.873 |
| Statin | 6 (4) | 25 (16.7) | 0.390 |
| Mean of death (year) | 2.6 ± 0.7 | 1.7 ± 1.1 | <0.001 |
| Time of CPB (minutes) | 112.43 ± 16.91 | ||
| Duration of cross-clamping (minutes) | 74.6 ± 6.92 | ||
| IT (hours) | 26 (2-55) | ||
| ICU stay (days) | 7 (3-12) | ||
| Mortality n (%) | |||
| 1 year | 1 (2.6) | 38 (33.9) | <0.001 |
| 1-3 years | 5 (13.5) | 25 (33.8) | 0.023 |
Univariate and multivariate cox regression analyses for predicting first-year mortality
Multivariate Cox proportional-hazards model including the variables in univariate analysis and also variables found to be significantly different between groups I and II with forward stepwise method.
CI: confidence interval; HR: hazard ratio; LDL-C, low-density lipoprotein cholesterol; ACEI, angiotensinogen-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ASA, acetylsalicylic acid; CABG, coronary artery bypass grafting
| Univariate | Multivariate | |||||
| Variables | p | HR | 95% CI | p | HR | 95% CI |
| Age | 0.520 | 1.032 | 0.938-1.135 | |||
| Syntax score | 0.358 | 1.024 | 0.973-1.077 | |||
| Diabetes mellitus | 0.301 | 1.481 | 0.703-3.120 | |||
| Hypertension | 0.830 | 1.072 | 0.569-2.019 | |||
| Hemoglobin levels | 0.035 | 0.828 | 0.696-0.987 | 0.027 | 0.824 | 0.694-0.979 |
| Creatinine | 0.746 | 0.835 | 0.281-0.484 | |||
| Serum glucose | 0.772 | 0.999 | 0.989-1.009 | |||
| LDL-C | 0.286 | 1.004 | 0.996-1.012 | |||
| Usage of beta blocker | 0.815 | 0.927 | 0.492-1.746 | |||
| Usage of ACEI/ARB | 0.830 | 0.933 | 0.495-1.757 | |||
| Usage of ASA | 0.960 | 0.982 | 0.478-2.014 | |||
| Usage of statin | 0.993 | 0.996 | 0.458-2.168 | |||
| Treatment method (CABG) | 0.007 | 0.065 | 0.009-0.475 | 0.007 | 0.064 | 0.009-0.467 |
Figure 1Kaplan-Meier analysis for all-cause mortality at first year
CABG: coronary artery bypass grafting
Figure 2Kaplan-Meier analysis for all-cause mortality at third year
CABG: coronary artery bypass grafting
Univariate and multivariate cox regression analyses for predicting third-year mortality
Multivariate Cox proportional-hazards model including the variables in univariate analysis and also variables found to be significantly different between groups I and II with forward stepwise method.
CI: confidence interval; HR: hazard ratio; LDL-C: low-density lipoprotein cholesterol; ACEI: angiotensinogen-converting enzyme inhibitor; ARB: angiotensin receptor blocker; ASA: acetylsalicylic acid; CABG: coronary artery bypass grafting
| Univariate | Multivariate | |||||
| Variables | p | HR | 95% CI | p | HR | 95% CI |
| Age | 0.311 | 1.038 | 0.966-1.116 | |||
| Syntax score | 0.541 | 0.988 | 0.951-1.027 | |||
| Diabetes mellitus | 0.472 | 1.214 | 0.717-2.055 | |||
| Hypertension | 0.625 | 1.124 | 0.703-1.798 | |||
| Creatinine | 0.498 | 0.738 | 0.307-1.775 | |||
| Serum glucose | 0.880 | 0.999 | 0.992-1.007 | |||
| Hemoglobin levels | 0.043 | 0.875 | 0.770-0.996 | 0.028 | 0.866 | 0.762-0.984 |
| LDL-C | 0.183 | 1.004 | 0.998-1.010 | |||
| Usage of beta blocker | 0.648 | 0.895 | 0.558-1.438 | |||
| Usage of ACEI/ARB | 0.830 | 0.933 | 0.495-1.757 | |||
| Usage of ASA | 0.811 | 0.938 | 0.554-1.588 | |||
| Usage of statin | 0.603 | 0.852 | 0.467-1.557 | |||
| Method of treatment (CABG) | 0.001 | 0.314 | 0.156-0.633 | 0.001 | 0.305 | 0.151-0.615 |